Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Tempus AI, Inc. (NASDAQ:TEM) grew its share prices by 29.7 percent week-on-week to end Friday’s trading at $89.44 apiece ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...